Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.58 |
| ▸ | MAOA | P21397 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | CALML3 | P27482 | 1/20 | 0.58 |
| ▸ | SDHA | P31040 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 11/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090602 | 1.00 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL14310688 | 0.92 | MAOB (0.64) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL3396464 | 0.91 | MAOB (0.60) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7847412 | 0.91 | MAOB (0.62) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL3394709 | 0.91 | MAOB (0.60) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7847416 | 0.91 | MAOB (0.62) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL2088355 | 0.90 | MAOB (0.59) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL8577685 | 0.89 | MAOB (0.73) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5412018 | 0.89 | MAOB (0.73) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL7847408 | 0.88 | MAOB (0.61) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329908-B2 | Dual action antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2011-03-10 | — | — | US | disclosed |
| US-7820823-B2 | Dual action antibiotics | Morphochem Aktiengesellschaft Fur Kominatorische Chemi (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20050096343-A1 | Dual action antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2005-05-05 | — | — | US | disclosed |
| EP-1432705-A2 | DUAL ACTION ANTIBIOTICS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003032962-A2 | DUAL ACTION ANTIBIOTICS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003031441-A1 | MULTIPLE ACTION COMPOUNDS | MORPHOCHEN AKTIENGESELLSCHAFT FÜR KOMBINATORISCHE CHEMIE (DE) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003031443-A1 | DUAL ACTIONS ANTIBIOTICS COMPRISING A OXAZOLDINONE AND A QUINOLONE OR NAPHTHYRIDINONE MOIETY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096343-A1 | Dual action antibiotics | SLC11A2, MRPL21, MAP2K5 | MAOB 1198/4885MAOA 905/4885LMNA 3271/4885 |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | SLC11A2, MRPL21, MAP2K5 | MAOB 1261/4885MAOA 978/4885LMNA 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.